Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds
Mustang Bio (NASDAQ: MBIO) has entered into a definitive agreement for the exercise of existing warrants to purchase 16,877,638 shares of common stock at $0.237 per share, expected to generate approximately $4 million in gross proceeds. In exchange, the company will issue new unregistered warrants to purchase 33,755,276 shares at $0.27 per share. The new warrants will be exercisable after stockholder approval, with half having a five-year term and half having a twelve-month term. H.C. Wainwright & Co. is acting as the exclusive placement agent. The proceeds will be used for working capital and general corporate purposes.
Mustang Bio (NASDAQ: MBIO) ha stipulato un accordo definitivo per l'esercizio di warrant esistenti per l'acquisto di 16.877.638 azioni di azioni ordinarie a $0,237 per azione, previsto di generare circa $4 milioni in proventi lordi. In cambio, la società emetterà nuovi warrant non registrati per acquistare 33.755.276 azioni a $0,27 per azione. I nuovi warrant saranno esercitabili dopo l'approvazione degli azionisti, con metà avente un termine di cinque anni e l'altra metà un termine di dodici mesi. H.C. Wainwright & Co. funge da agente di collocamento esclusivo. I proventi saranno utilizzati per capitale circolante e scopi aziendali generali.
Mustang Bio (NASDAQ: MBIO) ha firmado un acuerdo definitivo para el ejercicio de los warrants existentes para comprar 16,877,638 acciones de acciones comunes a $0.237 por acción, que se espera genere aproximadamente $4 millones en ingresos brutos. A cambio, la empresa emitirá nuevos warrants no registrados para comprar 33,755,276 acciones a $0.27 por acción. Los nuevos warrants serán ejercitables tras la aprobación de los accionistas, con la mitad teniendo un plazo de cinco años y la otra mitad un plazo de doce meses. H.C. Wainwright & Co. actúa como agente de colocación exclusivo. Los ingresos se utilizarán para capital de trabajo y propósitos corporativos generales.
머스탱 바이오 (NASDAQ: MBIO)는 16,877,638주의 보통주를 주당 $0.237에 매입할 수 있는 기존 워런트의 행사에 대한 최종 계약을 체결했습니다. 이는 약 $4백만의 총 수익을 창출할 것으로 예상됩니다. 그 대가로, 회사는 33,755,276주를 주당 $0.27에 매입할 수 있는 새로운 비등록 워런트를 발행할 것입니다. 새로운 워런트는 주주 승인 후 행사할 수 있으며, 절반은 5년의 기간을 갖고, 나머지 절반은 12개월의 기간을 가집니다. H.C. Wainwright & Co.는 독점 배치 에이전트로 활동하고 있습니다. 수익은 운영 자본 및 일반 기업 목적에 사용될 것입니다.
Mustang Bio (NASDAQ: MBIO) a conclu un accord définitif pour l'exercice de warrants existants visant à acheter 16 877 638 actions ordinaires à 0,237 $ par action, ce qui devrait générer environ 4 millions $ de revenus bruts. En échange, l'entreprise émettra de nouveaux warrants non enregistrés pour acheter 33 755 276 actions à 0,27 $ par action. Les nouveaux warrants seront exerçables après l'approbation des actionnaires, la moitié ayant une durée de cinq ans et l'autre moitié une durée de douze mois. H.C. Wainwright & Co. agit en tant qu'agent de placement exclusif. Les revenus seront utilisés pour le fonds de roulement et les objectifs généraux de l'entreprise.
Mustang Bio (NASDAQ: MBIO) hat einen endgültigen Vertrag zur Ausübung bestehender Warrants zum Kauf von 16.877.638 Aktien zu einem Preis von $0,237 pro Aktie unterzeichnet, was voraussichtlich rund $4 Millionen an Bruttoerlösen generieren wird. Im Gegenzug wird das Unternehmen neue nicht registrierte Warrants zum Kauf von 33.755.276 Aktien zu $0,27 pro Aktie ausgeben. Die neuen Warrants werden nach der Zustimmung der Aktionäre ausübbar sein, wobei die Hälfte eine Laufzeit von fünf Jahren und die andere Hälfte eine Laufzeit von zwölf Monaten hat. H.C. Wainwright & Co. fungiert als exklusiver Platzierungsagent. Die Erlöse sollen für Betriebskapital und allgemeine Unternehmenszwecke verwendet werden.
- Secured $4 million in immediate gross proceeds through warrant exercise
- Successfully registered shares for resale under Form S-1
- Potential dilution from issuance of 16.9M new shares
- Additional future dilution risk from 33.8M new warrant shares
- New warrants issued at only 13.9% premium to previous warrant exercise price
Insights
This warrant exercise represents a significant capital raise for Mustang Bio, bringing in
The transaction effectively doubles the potential dilution through new warrants covering 33.7 million shares, split between 5-year and 12-month terms. While the higher exercise price of
WORCESTER, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 16,877,638 shares of its common stock having an exercise price of
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
In consideration for the immediate exercise of the existing warrants for cash, the Company will issue new unregistered warrants to purchase up to an aggregate of 33,755,276 shares of common stock. The new warrants will have an exercise price of
The offering is expected to close on or about October 25, 2024, subject to satisfaction of customary closing conditions. Mustang currently intends to use the net proceeds from the offering for working capital and general corporate purposes.
The new warrants described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Regulation D promulgated thereunder and, along with the shares of common stock issuable upon exercise of the new warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the new warrants issued in the private placement and the shares of common stock underlying the new warrants may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The Company has agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock issuable upon the exercise of the new warrants.
This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Mustang Bio
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR-T therapies. Mustang’s common stock is registered under the Securities Exchange Act of 1934, as amended, and Mustang files periodic reports with the SEC. Mustang was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.mustangbio.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. These forward-looking statements, include, but are not limited to, statements regarding the completion of the offering, the satisfaction of customary closing conditions related to the offering, the anticipated use of proceeds therefrom and the receipt of Stockholder Approval, any statements relating to our workforce reduction and other alternatives, growth strategy and product development programs, including the timing of and our ability to make regulatory filings such as INDs and other applications and to obtain regulatory approvals for our product candidates, statements concerning the potential of therapies and product candidates and any other statements that are not historical facts. Actual events or results may differ materially from those described herein due to a number of risks and uncertainties. Risks and uncertainties include, among other things, risks that any actual or potential clinical trials described herein may not initiate or complete in sufficient timeframes to advance the Company’s corporate objectives, or at all, or that promising early results obtained therefrom may not be replicable, risks related to the satisfaction of the conditions necessary to transfer the lease of the Company’s manufacturing facility to a potential transferee and receive the contingent payment in connection with the Company’s sale of its manufacturing facility in the anticipated timeframe or at all; whether the purchaser of the Company’s manufacturing facility is able to successfully perform its obligation to produce the Company’s products under the manufacturing services agreement on a timely basis and to acceptable standards; disruption from the sale of the Company’s manufacturing facility making it more difficult to maintain business and operational relationships; negative effects of the announcement or the consummation of the transaction on the market price of the Company’s common stock; significant transaction costs; the development stage of the Company’s primary product candidates, our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; the ability to execute on strategic or other alternatives; as well as other risks described in Part I, Item 1A, “Risk Factors,” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, subsequent Quarterly Reports on Form 10-Q and our other filings we make with the SEC. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by applicable law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Company Contacts:
Jaclyn Jaffe and Nicole McCloskey
Mustang Bio, Inc.
(781) 652-4500
ir@mustangbio.com
FAQ
How much money did Mustang Bio (MBIO) raise from warrant exercise in October 2024?
What is the exercise price of Mustang Bio's (MBIO) new warrants issued in October 2024?
How many new warrant shares did Mustang Bio (MBIO) issue in October 2024?